Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol: Cycle control, lipid effects, and user satisfaction

Contraception

Volumn 59, Issue 3, 1999, Pages 161-166

  Sulak, Patricia ^a   Lippman, Joel ^b   Siu, Cynthia ^b   Massaro, Joseph ^c   Godwin, Amy ^b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Androgens; Cycle control; Ethinyl estradiol; Lipids; Norethindrone acetate; Norgestimate; Oral contraceptives

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORETHISTERONE; NORGESTIMATE; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVULATION INHIBITION; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL;

ANDROGENS; CONTRACEPTION; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIPIDS; MENSTRUAL CYCLE; NORETHINDRONE; NORGESTREL; PATIENT SATISFACTION;

EID: 0033002667     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00026-8     Document Type: Article

References (12)

1. Bounds W., Vessey M., Wiggins P. A randomized double-blind trial of low-dose combined oral contraceptives. Br J Obstet Gynaecol. 86:1979;325-329.
2. A randomized, double-blind study of six combined oral contraceptives. Contraception. 25:1982;231-241.
3. Carr B.R., Ory H. Estrogen and progestin components of oral contraceptives relationship to vascular disease . Contraception. 55:1997;267-272.
4. Darney P.D. OC practice guidelines minimizing side effects . Int J Fertil Womens Med. 42:(suppl 1):1997;158-169.
5. Andolsek K. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet Gynecol. 156:(suppl):1992;22-26.
6. Kafrissen M.E. A norgestimate-containing oral contraceptive review of clinical studies . Am J Obstet Gynecol. 165:1992;1616-1622.
7. Gauthier A., Upmalis D., Dain M.-P. Clinical evaluation of a new triphasic oral contraceptive norgestimate and ethinyl estradiol . Acta Obstet Gynecol Scand. 71:(suppl 156):1992;27-33.
8. Runnebaum B., Grunwald K., Rabe T. The efficacy and tolerability of norgestimate/ ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol) results of an open, multicenter study of 59,701 women . Am J Obstet Gynecol. 166:1992;1963-1968.
9. Huber J. Clinical experience with a new norgestimate-containing oral contraceptive. Int J Fertil. 36:(suppl):1991;25-31.
10. Lippman J.S., Shangold G.A. A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol. Int J Fertil Womens Med. 42:1997;230-239.
11. Zeger S.L., Liang K.-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 42:1986;121-130.
12. Carr B.R. Uniqueness of oral contraceptive progestins. Contraception. 58:(suppl):1998;23-27.